Pharma News

Some doctors may recommend that patients with the flu take acetaminophen, or paracetemol, to relieve their symptoms; however, a new randomized clinical trial found no benefits to the over-the-counter medication in terms of fighting the influenza virus or reducing patients' temperature or other symptoms.

Are you a green tea lover? Read this carefully as the cup packed with anti-oxidants and other health benefits may adversely affect your fertility and development in case of frequent use, warn researchers.

Scientists have deployed a new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action. The finding by the Scripps Research Institute (TSRI), US, may lead to a new type of diabetes treatment by enabling researchers quickly find drug candidates that activate cellular receptors in desired ways.

[adsense:336x280:8701650588]

For the first time, researchers led by the Imperial College London, have genetically modified malarial mosquitoes so that they carry a gene that disrupts egg production in female mosquitoes.

Men diagnosed with infertility are at higher risk of diabetes, heart disease, alcohol abuse and drug abuse compared to fertile men, a new study has revealed.

Dr. Reddy ’s announced  the signing of a Memorandum of Understanding  (MoU) with The Life Sciences Sector  Skill Development Council  (LSSSDC)  and  Vishnu  Institute of Pharmaceutical Education and Research (VIPER) .The MoU is aimed at fostering market research collaboration between LSSSDC and industry par tners , that in turn will help align educational courses to industry requirements.The MoU will also collaborate to create pharmaceutical,biotechnology and clinical research occupation standards, as well as establish acompetency matrix for job roles in the pharmaceutical sector.

Amgen and Merck known as MSD outside the United States and Canada,  announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen’s CD19 bispecific T cell engager (BiTE®), and KEYTRUDA is Merck’s anti-PD-1 antibody. The study is an open-label, multicenter, randomized trial to evaluate safety and efficacy in patients with DLBCL.

Gilead Sciences, Inc. announced that its Marketing Authorization Application (MAA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection, has been fully validated and is now under assessment by the European Medicines Agency (EMA). The data included in the application, which was submitted on November 17, 2015, support the use of SOF/VEL among patients with genotype 1-6 HCV infection, including patients with compensated and decompensated cirrhosis.

The United States Food and Drug Administration (FDA) has granted Fast Track designation to Trevena's oliceridine (TRV130) for the management of moderate-to-severe acute pain. Oliceridine is being developed as a potential replacement for currently approved intravenous opioid analgesics.